STOCK TITAN

Mediwound - MDWD STOCK NEWS

Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.

MediWound Ltd (Nasdaq: MDWD) is a biopharmaceutical innovator developing enzymatic therapeutics for non-surgical wound care. This page provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic developments.

Access consolidated information about NexoBrid adoption, EscharEx clinical trials, and pipeline progress. Stay informed about financial results, partnership announcements, and market expansion initiatives directly impacting MediWound's position in wound care innovation.

Key updates include FDA/EMA regulatory decisions, burn treatment protocols, chronic wound therapy breakthroughs, and peer-reviewed research findings. All content is verified through primary sources to ensure accuracy for investment and clinical decision-making.

Bookmark this page for streamlined access to MediWound's latest developments. Combine our updates with SEC filings and earnings call transcripts for comprehensive analysis of this enzymatic therapeutics leader.

Rhea-AI Summary

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Ofer Gonen will engage in a fireside chat on Wednesday, October 16, 2024, at 9:30 a.m. ET. The discussion will be hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim.

Interested parties can register to attend the virtual fireside chat through the provided link. Additionally, the MediWound management team will be available for one-on-one meetings during the summit. Investors wishing to schedule a meeting are advised to contact their Maxim representative.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Ofer Gonen will engage in a fireside chat on September 10, 2024, at 3:30 p.m. ET.

The discussion, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research, will be available via live webcast. Investors and interested parties can access the webcast through a provided link or on MediWound's website under the Events & Presentations page in the Investors section.

This presentation offers an opportunity for investors to gain insights into MediWound's latest developments and future prospects in the field of next-generation enzymatic therapeutics for tissue repair.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.34%
Tags
conferences
-
Rhea-AI Summary

MediWound (Nasdaq: MDWD) has announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for use in pediatric patients aged newborn through eighteen with deep partial- and/or full-thickness thermal burns. This approval expands NexoBrid's use to all age groups in the U.S., aligning with its approvals in the European Union and Japan.

The approval was supported by the results of the global Phase III Children Innovation Debridement Study (CIDS), funded by BARDA, as well as additional pediatric data from Phase III and Phase II studies. This milestone is significant as pediatric burn victims represent over 30% of the total burn population, and NexoBrid offers a non-surgical alternative to the current traumatic standard of care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
none
Rhea-AI Summary

MediWound (MDWD) reported Q2 2024 financial results and provided a company update. Key highlights include:

1. Completed construction of new NexoBrid® manufacturing facility, increasing capacity sixfold.

2. Secured €16.25 million EIC funding to expand EscharEx® development for diabetic foot ulcers.

3. Raised $25 million in strategic investment led by Mölnlycke Health Care.

4. Q2 revenue increased to $5.1 million, up from $4.8 million in Q2 2023.

5. Net loss of $6.3 million in Q2 2024, compared to net profit of $0.9 million in Q2 2023.

6. Cash position of $29.7 million as of June 30, 2024.

7. NexoBrid U.S. launch gaining momentum with 70+ burn centers submitting to P&T committees.

8. EscharEx Phase III study for venous leg ulcers to begin in H2 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
-
Rhea-AI Summary

MediWound (Nasdaq: MDWD) announced positive results from the U.S. NexoBrid® Expanded Access Protocol (NEXT). The study, conducted at 29 burn centers, involved 239 patients with deep partial and full-thickness thermal burns. Key findings include:

- 94.9% of adults and 100% of children achieved complete debridement
- Only 4.2% of adults required surgical excision after NexoBrid treatment
- Time to complete eschar removal was less than one day for all patients
- Median time to wound closure was 22 days for adults and 28 days for children
- Median hospitalization duration was 10 days for both adults and children

The results confirm NexoBrid's safety and efficacy in eschar removal, significantly reducing surgical procedures for burn patients. The safety data was consistent with NexoBrid's established profile, with no new concerns identified.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
none
-
Rhea-AI Summary

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced it will release its Q2 2024 financial results on August 14, 2024. The company will host a conference call and webcast at 8:30 am Eastern Time on the same day to discuss the results and provide corporate updates.

Investors and interested parties can join the call using the following details:

  • Toll-Free: 1-833-630-1956
  • Israel: 1-80-921-2373
  • International: 1-412-317-1837
A webcast link is also available, and an archived version will be accessible on MediWound's website for replay after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
conferences earnings
Rhea-AI Summary

MediWound (Nasdaq: MDWD) has announced the publication of its Phase II ChronEx study results for EscharEx® in treating Venous Leg Ulcers (VLU) in THE LANCET's eClinicalMedicine. The study, conducted across 20 medical centers in the US, Europe, and Israel, demonstrated EscharEx's superiority over non-surgical standard of care in debridement and promoting healthy granulation tissue.

Key findings include:

  • 63.0% complete debridement rate for EscharEx vs. 30.2% for placebo and 13.3% for non-surgical standard of care
  • Median time to complete debridement: 9 days for EscharEx vs. 63 days for placebo
  • 50.0% incidence of complete cover with healthy granulation tissue for EscharEx vs. 25.6% for placebo
  • Comparable safety profile to placebo and non-surgical standard of care
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
-
Rhea-AI Summary

MediWound (Nasdaq: MDWD) has been awarded €16.25 million in blended funding from the European Innovation Council (EIC) Accelerator program. This funding will significantly advance the development of EscharEx, MediWound's innovative treatment for diabetic foot ulcers (DFUs). The package includes a €2.5 million grant and an investment with terms to be finalized.

This support will enable MediWound to expedite the market introduction of EscharEx by four years, addressing a substantial market of up to 34 million diabetic patients in the US and Europe who are at risk of developing DFUs. The funding not only recognizes EscharEx's potential impact on patients but also allows MediWound to develop it for DFUs in parallel with their advanced program for venous leg ulcers (VLUs).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
none
-
Rhea-AI Summary

Mölnlycke Health Care, a leading MedTech company, has announced a $15 million investment in MediWound (Nasdaq: MDWD) through a private investment in public equity (PIPE). MediWound specializes in next-generation enzymatic therapeutics for non-surgical wound debridement. The investment aligns with Mölnlycke's strategy to bring radical innovations to wound care and improve clinical outcomes.

As part of the collaboration agreement, Mölnlycke will have a representative attend MediWound's R&D Committee meetings and participate in potential strategic partnership discussions. This partnership aims to support Mölnlycke's mission to 'help free patients from the burden of wounds' and strengthen MediWound's strategic plans to create long-term value for stakeholders and improve patient care standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
none
Rhea-AI Summary

MediWound (Nasdaq: MDWD) has announced a $25 million strategic private placement financing, led by Mölnlycke Health Care with a $15 million investment. The company will sell 1,453,488 ordinary shares at $17.20 per share. The proceeds will be used to advance EscharEx pre-commercial activities, develop large-scale manufacturing capabilities, and support general corporate purposes.

Alongside the investment, MediWound and Mölnlycke have entered into a collaboration agreement, granting Mölnlycke specific rights, including representation in MediWound's R&D Committee and participation in potential strategic partnerships. The agreement includes a stand-still clause limiting Mölnlycke's ownership to 9.99% of MediWound's outstanding shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
private placement
Mediwound

Nasdaq:MDWD

MDWD Rankings

MDWD Stock Data

184.81M
7.99M
19.75%
47.68%
8.65%
Biotechnology
Healthcare
Link
Israel
Yavne